{
    "root": "688cf25c-190e-40bb-bbe2-090b60e3e63d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Pioglitazole and metformin hydrochloride"
    },
    "value": "20250506",
    "ingredients": [
        {
            "name": "PIOGLITAZONE HYDROCHLORIDE",
            "code": "JQT35NPK6C"
        },
        {
            "name": "METFORMIN HYDROCHLORIDE",
            "code": "786Z46389E"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "pioglitazone metformin hydrochloride tablets indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus limitations pioglitazone metformin hydrochloride tablets recommended treat type 1 diabetes mellitus diabetic ketoacidosis .",
    "contraindications": "• obtain liver tests initiation . abnormal , caution treating pioglitazone metformin hydrochloride , investigate probable cause , treat ( possible ) , follow appropriately . ( 2.1 ) • take orally meals reduce gastrointestinal metformin ( 2.1 ) • individualize starting dose based patient ’ current regimen titrate gradually , needed assessing therapeutic response tolerability . maximum recommended total daily pioglitazone 45 mg metformin 2,550 mg. ( 2.2 ) • recommended starting patients nyha class class ii congestive heart failure 15 mg pioglitazone 850 mg metformin hcl orally daily . ( 2.4 ) • prior initiation , assess renal function estimated glomerular filtration rate ( egfr ) . ( 2.2 ) contraindicated patients egfr 30 ml/min initiation recommended patients egfr 30 45 ml/min assess risk/benefit continuing pioglitazone metformin hydrochloride egfr falls 45 ml/min discontinue egfr falls 30 ml/min • monitor patients events related fluid retention initiation dose increases . ( 2.4 ) • pioglitazone metformin hydrochloride may need discontinued time , prior , iodinated contrast imaging procedures . ( 2.6 )",
    "warningsAndPrecautions": "pioglitazone metformin hydrochloride tablets , usp available 15 mg pioglitazone ( base ) /500 mg metformin hydrochloride 15 mg pioglitazone ( base ) /850 mg metformin hydrochloride tablets follows : pioglitazone metformin hydrochloride tablets , usp 15 mg / 500 mg : white off-white coloured , capsule shaped , film-coated tablets debossed 'c27 ' one side plain side available follows : bottles 60 tablets ( ndc 33342-176-09 ) bottles 100 tablets ( ndc 33342-176-11 ) bottles 180 tablets ( ndc 33342-176-57 ) bottles 1000 tablets ( ndc 33342-176-44 ) cartons 100 unit dose tablets ( 10×10 ) ( ndc 33342-176-12 ) pioglitazone metformin hydrochloride tablets , usp 15 mg / 850 mg : white off-white coloured , capsule shaped , film-coated tablets debossed 'c28 ' one side plain side . bottles 60 tablets ( ndc 33342-177-09 ) bottles 100 tablets ( ndc 33342-177-11 ) bottles 180 tablets ( ndc 33342-177-57 ) bottles 1000 tablets ( ndc 33342-177-44 ) cartons 100 unit dose tablets ( 10×10 ) ( ndc 33342-177-12 ) storage : store 20º 25º c ( 68º 77º f ) ; excursions permitted 15º 30º c ( 59º 86º f ) [ usp controlled room temperature ] . keep container tightly closed , protect moisture humidity .",
    "adverseReactions": "pioglitazone metformin hydrochloride tablets contraindicated patients : • established nyha class iii iv heart failure time pioglitazone metformin hydrochloride tablets initiation [ boxed warning ] . • severe renal impairment ( egfr 30 ml/min ) [ ( 5.2 ) ] . • history serious hypersensitivity pioglitazone , metformin hcl , excipients pioglitazone metformin hydrochloride tablets . • acute chronic metabolic acidosis , including diabetic ketoacidosis [ ( 5.2 ) ] .",
    "indications_original": "Pioglitazone and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus \n                  \n                     Limitations of Use\n                  \n                  Pioglitazone and metformin hydrochloride tablets is not recommended to treat type 1 diabetes mellitus or diabetic ketoacidosis.",
    "contraindications_original": "• Obtain liver tests before initiation. If abnormal, use caution when treating with pioglitazone and metformin hydrochloride, investigate the probable cause, treat (if possible), and follow appropriately. ( 2.1 ) • Take orally with meals to reduce gastrointestinal adverse reactions with metformin ( 2.1 ) • Individualize the starting dose based on the patient’s current regimen and titrate the dosage gradually, as needed after assessing therapeutic response and tolerability. The maximum recommended total daily dosage is pioglitazone 45 mg and metformin 2,550 mg. ( 2.2 ) • Recommended starting dosage in patients with NYHA Class I or Class II congestive heart failure is 15 mg of pioglitazone and 850 mg of metformin HCl orally once daily. ( 2.4 ) • Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR). ( 2.2 ) o Contraindicated in patients with eGFR below 30 mL/min o Initiation is not recommended in patients with eGFR between 30 to 45 mL/min o Assess risk/benefit of continuing pioglitazone and metformin hydrochloride if eGFR falls below 45 mL/min o Discontinue if eGFR falls below 30 mL/min • Monitor patients for adverse events related to fluid retention after initiation and dose increases. ( 2.4 ) • Pioglitazone and metformin hydrochloride may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures. (2.6)",
    "warningsAndPrecautions_original": "Pioglitazone and metformin hydrochloride tablets, USP are available in 15 mg pioglitazone (as the base)/500 mg metformin hydrochloride and 15 mg pioglitazone (as the base)/850 mg metformin hydrochloride tablets as follows: \n                  Pioglitazone and metformin hydrochloride tablets, USP 15 mg / 500 mg: White to off-white coloured, capsule shaped, film-coated tablets debossed with 'C27' on one side and plain on the other side and are available as follows: \n                  Bottles of 60 tablets           (NDC 33342-176-09)  Bottles of 100 tablets         (NDC 33342-176-11) Bottles of 180 tablets         (NDC 33342-176-57) Bottles of 1000 tablets       (NDC 33342-176-44)  Cartons of 100 unit dose tablets (10×10)  (NDC 33342-176-12)\n                  Pioglitazone and Metformin hydrochloride tablets, USP 15 mg / 850 mg: White to off-white coloured, capsule shaped, film-coated tablets debossed with 'C28' on one side and plain on the other side.\n                  Bottles of 60 tablets           (NDC 33342-177-09)  Bottles of 100 tablets         (NDC 33342-177-11) Bottles of 180 tablets         (NDC 33342-177-57)   Bottles of 1000 tablets       (NDC 33342-177-44)  Cartons of 100 unit dose tablets (10×10)  (NDC 33342-177-12)\n                  \n                     Storage: Store at 20º to 25º C (68º to 77º F); excursions permitted to 15º to 30º C (59º to 86º F) [see USP Controlled Room Temperature]. Keep container tightly closed, and protect from moisture and humidity.",
    "adverseReactions_original": "Pioglitazone and metformin hydrochloride tablets are contraindicated in patients with:\n                  • Established NYHA Class III or IV heart failure at the time of pioglitazone and metformin hydrochloride tablets initiation [see Boxed Warning].\n                      • Severe renal impairment (eGFR below 30 mL/min) [see Warnings and Precautions (5.2)].\n                      • A history of serious hypersensitivity to pioglitazone, metformin HCl, or any of the excipients in pioglitazone and metformin hydrochloride tablets. • Acute or chronic metabolic acidosis, including diabetic ketoacidosis [see Warnings and Precautions (5.2)]."
}